Form 4: Protara Therapeutics Director Luke Beshar Granted 24,000 Stock Options

Protara Therapeutics, Inc. Director Luke M. Beshar was granted 24,000 stock options with an exercise price of $3.26, vesting over one year.

Summary

• Luke M. Beshar, a Director of Protara Therapeutics, Inc. (TARA), was granted 24,000 stock options.
• The options have an exercise price of $3.26 per share.
• The grant date for these options was June 12, 2025.
• The options will vest in full on June 12, 2026, which is the first anniversary of the grant date, provided Mr. Beshar maintains continuous service on the Board.
• Additionally, the options will vest immediately upon a Change of Control.
• The expiration date for these stock options is June 11, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive or neutral event, as it aligns the director's interests with shareholder value and is a standard compensation practice. It indicates continued board engagement.

Positives

• The grant of stock options aligns the director's interests with shareholder value, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and continuous service from the director.

Future Outlook

The document indicates future vesting of stock options on June 12, 2026, contingent on the director's continuous service, and also upon a Change of Control, aligning future incentives.

Industry Context

This is a standard compensation practice for directors in the biotechnology or pharmaceutical industry, aiming to align their interests with long-term shareholder value. Such grants are common across publicly traded companies to incentivize performance and retention of key personnel.

Comparison to Industry Standards

• The grant of stock options to a director is a common form of equity compensation in publicly traded companies, particularly in the biotech sector where long-term value creation is paramount.
• While specific comparable companies or projects are not mentioned in this filing, similar grants are observed at companies like BioNTech SE, Moderna Inc., or Gilead Sciences, Inc., where executive and director compensation often includes significant equity components to incentivize innovation and market performance.
• The vesting schedule and exercise price are typical for annual director grants.

Stakeholder Impact

• Shareholders: Potential for alignment of director's interests with shareholder value; potential future dilution if options are exercised.

Next Steps

• The 24,000 stock options are scheduled to vest on June 12, 2026, subject to continuous service.
• The options will expire on June 11, 2035.

Key Dates

Recommendation

Keywords

Protara Therapeutics, TARA, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Grant, Luke Beshar